TXNRD2 and cardiomyopathy: TXNRD2 mutations demonstrate tissue-selective pathogenicity, primarily targeting adrenal fasciculata while sparing other high-energy organs—a stark contrast to systemic mitochondrial disorders caused by TXNRD2 defects (e.g., cardiomyopathy in encephalopathic forms).